Total Utang marang Modal OnKure Therapeutics Inc (OKUR)

OnKure Therapeutics Inc - logo grafis emiten OKUR

OnKure Therapeutics Inc (OKUR) maintains a strong reputation in the field of precision oncology, developing drugs tailored to specific genetic malfunctions. The technical foundation relies on the operation of modern laboratories and reserved plant capacities for mass production. A team of scientists, who efficiently manage venture capital, ensures the business's effectiveness. The shares shown on this price chart demonstrate a total debt-to-equity ratio of 0.01.

OnKure Therapeutics, Inc. (OKUR): Rasio Utang marang Ekuitas saka 08.10.2024 nganti 01.11.2026

Rincian metrik lan analitis perusahaan OnKure Therapeutics (OKUR)

- rega saham lan konsensus proyeksi valuasi:
Rega saham OnKure Therapeutics, Inc.|OKUR - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar OnKure Therapeutics|OKUR - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham OnKure Therapeutics|OKUR - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku onkuretherapeutics.com|OKUR - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal OnKure Therapeutics Inc|OKUR - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas OnKure Therapeutics, Inc.|OKUR - Kewajiban utang agregat|Utang marang nilai buku OnKure Therapeutics|OKUR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan OnKure Therapeutics|Indikator likuiditas cepet onkuretherapeutics.com
- data bathi resik lan rasio valuasi:
OKUR - Bathi resik
Pambiji fundamental perusahaan:OnKure Therapeutics Inc
Produk dadi OnKure Therapeutics, Inc.

This metric compares total liabilities to net assets, determining the degree of funding dependence on borrowed funds relative to equity. For OnKure Therapeutics Inc (OKUR), amidst a fierce biotech development race and high risks of research delays, avoiding excessive leverage is critical, and the financial leverage ratio (total debt-to-equity) allows for tracking the company's resilience to market shocks.

Analisis pesaing OnKure Therapeutics Inc

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Fate Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Utang marang Modal TScan TCRX|Utang marang Ekuitas Champions Oncology (CSBR)|XBIT - Utang marang Modal|Utang marang Ekuitas CEL-SCI CVM|OSTX: Rasio Utang marang Ekuitas|RADX - Utang marang Ekuitas|ARTV - Total Utang marang Modal|ANL (adlainortye.com) - Rasio Total Utang marang Ekuitas|verupharma.com (VERU) - Total Utang marang Modal|Utang marang Ekuitas Tempest Therapeutics, Inc.|XLO: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal RENB|MURA - Utang marang Modal|Kairos Pharma - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GDTC|CRIS: Rasio Total Utang marang Ekuitas|Apollomics, Inc. - Utang Agregat marang Modal|THAR: Total Utang marang Modal|Advanced Biomed - Rasio Kabeh Utang marang Dana Pribadi|GNPX (Genprex, Inc.) - Total Utang marang Modal|Utang marang Modal Calidi Bio CLDI|Utang marang Ekuitas Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLRX (Salarius)|Total Utang marang Modal Kitov Pharma PPBT|AONC - Utang marang Ekuitas|Utang Agregat marang Ekuitas BGNE|CKPT: Total Utang marang Modal|Utang marang Modal elevationoncology.com (ELEV)|Rasio Total Utang marang Ekuitas ICAD|Total Utang marang Modal Ikena|Rasio Total Utang marang Ekuitas NTBL (Notable Labs, Ltd.)|Utang Agregat marang Modal VIRX|Total Utang marang Modal MOR (MorphoSys)|Koefisien Total Utang marang Modal NAYA Biosciences Inc (NAYA)|Ascentage Pharma Group Ltd - Total Utang marang Modal